Vectura Group plc Board Change (6293Y)
March 06 2017 - 6:48AM
UK Regulatory
TIDMVEC
RNS Number : 6293Y
Vectura Group plc
06 March 2017
Vectura Group plc
Board Change
Trevor Phillips, Chief Operations Officer to step down at the
Annual General Meeting on 25 May 2017
Chippenham, UK - 6 March 2017: Vectura Group plc (LSE: VEC)
("Vectura", "the Group", "the Company"), an industry-leading device
and formulation business for inhaled airways disease, announces
that Trevor Phillips, Vectura's Chief Operations Officer and
President of US Operations ("COO"), will step down from the Board
at the AGM on 25 May 2017 and leave the Company on 31 May 2017.
Since joining Vectura Trevor has played an integral leadership
role in Vectura's successful development, including the acquisition
of Activaero in 2014 and the merger with Skyepharma in 2016.
Following the merger with Skyepharma, in which Trevor has headed
up the integration activities, Trevor has additionally led the
development of the Manufacturing, Device Industrialisation and
Supply Chain teams of the enlarged Vectura group. A recruitment
process will now commence for a suitably experienced individual to
lead the Group's Supply Chain and Manufacturing operations. This
new role will not be a Board position.
James Ward-Lilley, Chief Executive Officer, commented:
"I would like to extend my personal thanks to Trevor for the
support he has given me and for the highly professional way in
which he has carried out his role in the business. Trevor has been
with Vectura since 2010 and in that time he has been a significant
driver of the transition of the Group into the business it is
today. Having managed the initial integration of Skyepharma and
Vectura, Trevor and I agreed that the AGM would be an appropriate
time for him to transition out of the Company. The Board and I
would like to thank Trevor for his contribution throughout his
tenure, and we wish him well in his future endeavours."
The information required to be made available under section
430(2B) of the Companies Act 2006 in relation to Trevor Phillips
will be made available in the Investors section of the Company's
website www.vectura.com in due course.
- Ends -
Enquiries
Vectura Group plc +44 (0)1249 667700
Andrew Derodra - Chief Financial Officer
Fleur Wood - Director Communications
Elizabeth Knowles - Director Investor Relations and Analysis
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson vectura@consilium-comms.com
About Vectura
Vectura, a FTSE250 company listed on the London Stock Exchange
(LSE: VEC), is an industry-leading inhaled airways disease focused
business with proprietary formulation and devices across DPI, pMDI
and "smart" nebulisation platforms. With our extensive range of
technologies, capabilities and collaborations, we believe we can
become a leader in the development of inhalation products,
increasing our ability to help patients suffering from respiratory
diseases. In June 2016 Vectura completed a merger with Skyepharma
PLC.
Vectura has seven inhaled, four non-inhaled and ten oral
products marketed by partners with growing global royalty streams,
and a portfolio of drugs in clinical development, a number of which
have licence agreements with several global pharmaceutical and
biotechnology companies including Hikma, Novartis, Sandoz,
Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi,
Almirall, Janssen, and Tianjin KingYork.
For further information, please visit Vectura's website at
www.vectura.com.
Forward-looking statements
This press release contains forward-looking statements,
including statements about the discovery, development and
commercialisation of products. Various risks may cause Vectura's
actual results to differ materially from those expressed or implied
by the forward-looking statements, including: adverse results in
clinical development programmes; failure to obtain patent
protection for inventions; commercial limitations imposed by
patents owned or controlled by third parties; dependence upon
strategic alliance partners to develop and commercialise products
and services; difficulties or delays in obtaining regulatory
approvals to market products and services resulting from
development efforts; the requirement for substantial funding to
conduct research and development and to expand commercialisation
activities; and product initiatives by competitors. As a result of
these factors, prospective investors are cautioned not to rely on
any forward-looking statements. We disclaim any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAEAADKELKXEFF
(END) Dow Jones Newswires
March 06, 2017 07:48 ET (12:48 GMT)
Vectura (LSE:VEC)
Historical Stock Chart
From Apr 2024 to May 2024
Vectura (LSE:VEC)
Historical Stock Chart
From May 2023 to May 2024